Private groundbreaking ceremony was held on Tuesday, May 15 in Whitestown
INDIANAPOLIS (May 24, 2018) – PTS Diagnostics, a U.S.–based manufacturer of point-of-care biometric testing devices, today announced that they are expanding operations in Indianapolis and building a new global headquarters.
In order to support continued rapid growth, the in vitro diagnostics company is investing in additional manufacturing and office space, and moving their global headquarters to Whitestown. The new 135,000 square foot building is slated to open in June of 2019 on the southwest corner of Anson Blvd and C.R. 450 South.
A private groundbreaking ceremony with executives, architects, builders and representatives from PTS Diagnostics’ parent company, Sinocare, was held on the morning of Tuesday, May 15. A company-wide celebration is planned for summer 2018.
“PTS Diagnostics is still in high-growth mode, and our organization has evolved considerably in the past decade,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “As an organization, we pride ourselves on the ability to adhere to our core Hoosier values while scaling the business globally in accordance with growing demand and the expansion of our product lines. In addition to acquiring a manufacturing facility in California, we recently opened a sales office in Bangalore, India. In December, we announced the launch of a new retail point-of-care software for health screeners that is poised to create a niche in the expanding field of population health management.”
PTS Diagnostics currently has more than 150 employees in its flagship Indianapolis location and 86 employees in its Sunnyvale, California facility, which was acquired in late 2013. The company continues to grow much faster than the rate of industry growth, and this expansion will bring jobs to Indianapolis in the finance, marketing, chemistry, engineering, and manufacturing sectors, amongst others. Interested applicants are encouraged to monitor the PTS Diagnostics career center at ptsdiagnostics.com/career-center.html.
According to Indiana University’s Kelley School of Business, the economic impact of Indiana’s life sciences industry has climbed to more than $63 billion and is comprised of roughly 60,000 employees – making it one of the top states for in vitro diagnostics.
“The Browning/Duke Realty joint venture is proud to partner with PTS Diagnostics and assist them with the development of a building that is capable of meeting their growth and manufacturing needs,” said Mark Hosfeld, Vice President of Leasing and Development at Duke Realty. “Indiana has a booming life sciences sector and this new global headquarters represents a continued commitment to the point-of-care technology that will further solidify their place in this rapidly growing industry.”
About PTS Diagnostics
Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek ® products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our products to more than 140 countries around the globe. For more information, visit ptsdiagnostics.com.
About Browning
Founded in 1977, Browning remains one of the premier development companies in Indianapolis and is engaged in the acquisition, development, construction, leasing, management, ownership and disposition of investment real estate properties, primarily in the Indianapolis metropolitan area. In total, Browning has developed and constructed more than 25 million square feet of space of bulk industrial space. To learn more, visit: www.browninginvestments.com.
About Duke Realty Corporation
Duke Realty Corporation owns and operates approximately 149 million rentable square feet of industrial assets in 20 key U.S. logistics markets. Duke Realty is publicly traded on the NYSE under the symbol DRE and is listed on the S&P 500. The company maintains a Baa1 rating from Moody’s Investor Service and a BBB+ rating from Standard & Poor’s Financial Services. More information about Duke Realty Corporation is available at www.dukerealty.com. Duke Realty also can be followed on Twitter, LinkedIn, Facebook and YouTube.
